StockData
Veracyte, Inc. logo

Veracyte, Inc. (VCYT) stock

VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3034% below fair value
$24.23+0.22 (+0.92%)

Close on Nov 17, 2026Market cap $1.95BP/E 17.3Yield –

Veracyte total assets

Total assets on the balance sheet at the end of each period.

Veracyte's total assets was $1.49B at Jun 30, 2026. For fiscal 2025 it was $1.41B, up 8.2% from the year before. Over ten years it grew 34.0% a year on average. The highest annual figure on record is $1.41B in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.41B+8.2%
FY2024Dec 31, 2024$1.30B+16.6%
FY2023Dec 31, 2023$1.11B-3.6%
FY2022Dec 31, 2022$1.16B-2.6%
FY2021Dec 31, 2021$1.19B+159.8%
FY2020Dec 31, 2020$457.16M+66.1%
FY2019Dec 31, 2019$275.21M+128.1%
FY2018Dec 31, 2018$120.64M+53.3%
FY2017Dec 31, 2017$78.67M-22.1%
FY2016Dec 31, 2016$101.03M+34.3%
FY2015Dec 31, 2015$75.25M+16.1%
FY2014Dec 31, 2014$64.84M-18.6%
FY2013Dec 31, 2013$79.63M+317.6%
FY2012Dec 31, 2012$19.07M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.49B+10.6%
Q1 FY2026Mar 31, 2026$1.44B+9.2%
Q4 FY2025Dec 31, 2025$1.41B+8.2%
Q3 FY2025Sep 30, 2025$1.37B+7.3%
Q2 FY2025Jun 30, 2025$1.34B+8.9%
Q1 FY2025Mar 31, 2025$1.32B+9.6%
Q4 FY2024Dec 31, 2024$1.30B+16.6%
Q3 FY2024Sep 30, 2024$1.28B+13.3%
Q2 FY2024Jun 30, 2024$1.23B+6.3%
Q1 FY2024Mar 31, 2024$1.20B+3.7%
Q4 FY2023Dec 31, 2023$1.11B-3.6%
Q3 FY2023Sep 30, 2023$1.12B-0.1%
Q2 FY2023Jun 30, 2023$1.16B+1.5%
Q1 FY2023Mar 31, 2023$1.16B-1.4%
Q4 FY2022Dec 31, 2022$1.16B-2.6%
Q3 FY2022Sep 30, 2022$1.13B-5.1%
Q2 FY2022Jun 30, 2022$1.14B+11.4%
Q1 FY2022Mar 31, 2022$1.17B+14.5%
Q4 FY2021Dec 31, 2021$1.19B+159.8%
Q3 FY2021Sep 30, 2021$1.19B+161.2%
Q2 FY2021Jun 30, 2021$1.03B+300.2%
Q1 FY2021Mar 31, 2021$1.03B+283.8%
Q4 FY2020Dec 31, 2020$457.16M+66.1%
Q3 FY2020Sep 30, 2020$454.15M+74.5%
Q2 FY2020Jun 30, 2020$256.74M+1.7%
Q1 FY2020Mar 31, 2020$267.10M+116.2%
Q4 FY2019Dec 31, 2019$275.21M+128.1%
Q3 FY2019Sep 30, 2019$260.31M+118.6%
Q2 FY2019Jun 30, 2019$252.38M+285.5%
Q1 FY2019Mar 31, 2019$123.54M+73.5%
Q4 FY2018Dec 31, 2018$120.64M+53.3%
Q3 FY2018Sep 30, 2018$119.08M+42.3%
Q2 FY2018Jun 30, 2018$65.46M-25.9%
Q1 FY2018Mar 31, 2018$71.19M-23.1%
Q4 FY2017Dec 31, 2017$78.67M-22.1%
Q3 FY2017Sep 30, 2017$83.66M+20.1%
Q2 FY2017Jun 30, 2017$88.35M–
Q1 FY2017Mar 31, 2017$92.61M–
Q4 FY2016Dec 31, 2016$101.03M–
Q3 FY2016Sep 30, 2016$69.65M–

More Veracyte figures

See a number that looks wrong?